Welcome to the 1st International
Student Conference on
Industrial Pharmacy
President SC ISPE
Our conference is a pioneering event hosted by the
Poznan University of Medical Sciences and will be held
on the 7th and 8th of December, 2023. This conference
is a great opportunity to advance knowledge in the
field of pharmacy and provides a platform for students
to showcase their work.
The Event enables students to develop knowledge
especially in the field of pharmaceutical industry.
Moreover, it offers students a unique opportunity to
present their research through poster sessions and
presentations, fostering academic and professional
growth.
Our lectures boasts an impressive lineup of
distinguished speakers hailing from Poland, the United
Kingdom, and the Czech Republic, representing both
academia and industry. Their expertise will provide
invaluable insights into the dynamic world of industrial
pharmacy. Additionally, attendees can look forward to
a memorable Gala Night and engaging workshop
IVIVC for Extended-Release Hydrophilic Matrix Tablets in Consideration of Bio...Valentyn Mohylyuk
Purpose
When establishing IVIVC, a special problem arises by interpretation of averaged in vivo profiles insight of considerable individual variations in term of time and number of mechanical stress events in GI-tract. The objective of the study was to investigate and forecast the effect of mechanical stress on in vivo behavior in human of hydrophilic matrix tablets.
Methods
Dissolution profiles for the marketed products were obtained at different conditions (stirring speed, single- or repeatable mechanical stress applied) and convoluted into C-t profiles. Vice versa, published in vivo C-t profiles of the products were deconvoluted into absorption profiles and compared with dissolution profiles by similarity factor.
Results
Investigated hydrophilic matrix tablets varied in term of their resistance against hydrodynamic stress or single stress during the dissolution. Different scenarios, including repeatable mechanical stress, were investigated on mostly prone Seroquel® XR 50 mg. None of the particular scenarios fits to the published in vivo C-t profile of Seroquel® XR 50 mg representing, however, the average of individual profiles related to scenarios differing by number, frequency and time of contraction stress. When different scenarios were combined in different proportions, the profiles became closer to the original in vivo profile including a burst between 4 and 5 h, probably, due to stress-events in GI-tract.
Conclusion
For establishing IVIVC of oral dosage forms susceptible mechanical stress, a comparison of the deconvoluted individual in vivo profiles with in vitro profiles of different dissolution scenarios can be recommended.
Wurster Fluidised Bed Coating of Microparticles: Towards Scalable Production ...Valentyn Mohylyuk
Suspension of microparticles in an easy-to-swallow liquid is one approach to develop sustained-release formulations for children and patients with swallowing difficulties. However, to date production of sustained-release microparticles at the industrial scale has proven to be challenging. The aim of this investigation was to develop an innovative concept in coating sustained-release microparticles using industrial scalable Wurster fluidised bed to produce oral liquid suspensions. Microcrystalline cellulose cores (particle size <150 μm) were coated with Eudragit® NM 30 D and Eudragit® RS/RL 30 D aqueous dispersions using a fluidised bed coater. A novel approach of periodic addition of a small quantity (0.1% w/w) of dry powder glidant, magnesium stearate, to the coating chamber via an external port was applied throughout the coating process. This method significantly increased coating production yield from less than 50% to up to 99% compared to conventional coating
process without the dry powder glidant. Powder rheology tests showed that dry powder glidants increased the tapped density and decreased the cohesive index of coated microparticles. Reproducible microencapsulation of a highly water-soluble drug, metoprolol succinate, was achieved, yielding coated microparticles less than 200 μm in size with 20-h sustained drug release, suitable for use in liquid suspensions. The robust, scalable technology presented in this study offers an important solution to the long-standing challenges of formulating sustained-release dosage forms suitable for children and older people with swallowing difficulties.
In order to produce smaller droplets and compensate for the bigger droplets caused
by high viscosity fluids one can increase the pressure of the fluid. This will reduce the
droplet size according to the formula below
No more sampling! The Distek Opt-Diss 410 in-situ fiber optic UV system measures directly in the vessel, eliminating the need for conventional sampling, and with-it consumables like filters, tubing and syringes, saving time, labor, and money. Moving light rather than liquids also allows generating near real-time dissolution data and nearly limitless sample points as frequently as every five seconds.
PATVIS APA: visual inspection system for automated particle analysisValentyn Mohylyuk
- in-line or at-line process measurements
- simple installation in r & d or production of solid dosage forms
- portable, ergonomic and tool free
- ATEX and FDA CFR 21 part 11 compliant
Purpose
Fluid-bed coating of microparticles using aqueous polymer dispersions is a challenge due to particle agglomeration. Agglomeration is an undesirable phenomenon especially for modified release products resulting in inconsistent and unreliable coating thickness and drug release profile. Due to the small particle size and relatively high coating level, the determination of agglomerated particles is complicated and cannot be performed by common methods such as sieve analysis and observation under light microscope.
The objective of this study was to investigate appropriate methods to determine the internal structure of coated microparticles to support decision making in the formulation and coating process development.
Welcome to the 1st International
Student Conference on
Industrial Pharmacy
President SC ISPE
Our conference is a pioneering event hosted by the
Poznan University of Medical Sciences and will be held
on the 7th and 8th of December, 2023. This conference
is a great opportunity to advance knowledge in the
field of pharmacy and provides a platform for students
to showcase their work.
The Event enables students to develop knowledge
especially in the field of pharmaceutical industry.
Moreover, it offers students a unique opportunity to
present their research through poster sessions and
presentations, fostering academic and professional
growth.
Our lectures boasts an impressive lineup of
distinguished speakers hailing from Poland, the United
Kingdom, and the Czech Republic, representing both
academia and industry. Their expertise will provide
invaluable insights into the dynamic world of industrial
pharmacy. Additionally, attendees can look forward to
a memorable Gala Night and engaging workshop
IVIVC for Extended-Release Hydrophilic Matrix Tablets in Consideration of Bio...Valentyn Mohylyuk
Purpose
When establishing IVIVC, a special problem arises by interpretation of averaged in vivo profiles insight of considerable individual variations in term of time and number of mechanical stress events in GI-tract. The objective of the study was to investigate and forecast the effect of mechanical stress on in vivo behavior in human of hydrophilic matrix tablets.
Methods
Dissolution profiles for the marketed products were obtained at different conditions (stirring speed, single- or repeatable mechanical stress applied) and convoluted into C-t profiles. Vice versa, published in vivo C-t profiles of the products were deconvoluted into absorption profiles and compared with dissolution profiles by similarity factor.
Results
Investigated hydrophilic matrix tablets varied in term of their resistance against hydrodynamic stress or single stress during the dissolution. Different scenarios, including repeatable mechanical stress, were investigated on mostly prone Seroquel® XR 50 mg. None of the particular scenarios fits to the published in vivo C-t profile of Seroquel® XR 50 mg representing, however, the average of individual profiles related to scenarios differing by number, frequency and time of contraction stress. When different scenarios were combined in different proportions, the profiles became closer to the original in vivo profile including a burst between 4 and 5 h, probably, due to stress-events in GI-tract.
Conclusion
For establishing IVIVC of oral dosage forms susceptible mechanical stress, a comparison of the deconvoluted individual in vivo profiles with in vitro profiles of different dissolution scenarios can be recommended.
Wurster Fluidised Bed Coating of Microparticles: Towards Scalable Production ...Valentyn Mohylyuk
Suspension of microparticles in an easy-to-swallow liquid is one approach to develop sustained-release formulations for children and patients with swallowing difficulties. However, to date production of sustained-release microparticles at the industrial scale has proven to be challenging. The aim of this investigation was to develop an innovative concept in coating sustained-release microparticles using industrial scalable Wurster fluidised bed to produce oral liquid suspensions. Microcrystalline cellulose cores (particle size <150 μm) were coated with Eudragit® NM 30 D and Eudragit® RS/RL 30 D aqueous dispersions using a fluidised bed coater. A novel approach of periodic addition of a small quantity (0.1% w/w) of dry powder glidant, magnesium stearate, to the coating chamber via an external port was applied throughout the coating process. This method significantly increased coating production yield from less than 50% to up to 99% compared to conventional coating
process without the dry powder glidant. Powder rheology tests showed that dry powder glidants increased the tapped density and decreased the cohesive index of coated microparticles. Reproducible microencapsulation of a highly water-soluble drug, metoprolol succinate, was achieved, yielding coated microparticles less than 200 μm in size with 20-h sustained drug release, suitable for use in liquid suspensions. The robust, scalable technology presented in this study offers an important solution to the long-standing challenges of formulating sustained-release dosage forms suitable for children and older people with swallowing difficulties.
In order to produce smaller droplets and compensate for the bigger droplets caused
by high viscosity fluids one can increase the pressure of the fluid. This will reduce the
droplet size according to the formula below
No more sampling! The Distek Opt-Diss 410 in-situ fiber optic UV system measures directly in the vessel, eliminating the need for conventional sampling, and with-it consumables like filters, tubing and syringes, saving time, labor, and money. Moving light rather than liquids also allows generating near real-time dissolution data and nearly limitless sample points as frequently as every five seconds.
PATVIS APA: visual inspection system for automated particle analysisValentyn Mohylyuk
- in-line or at-line process measurements
- simple installation in r & d or production of solid dosage forms
- portable, ergonomic and tool free
- ATEX and FDA CFR 21 part 11 compliant
Purpose
Fluid-bed coating of microparticles using aqueous polymer dispersions is a challenge due to particle agglomeration. Agglomeration is an undesirable phenomenon especially for modified release products resulting in inconsistent and unreliable coating thickness and drug release profile. Due to the small particle size and relatively high coating level, the determination of agglomerated particles is complicated and cannot be performed by common methods such as sieve analysis and observation under light microscope.
The objective of this study was to investigate appropriate methods to determine the internal structure of coated microparticles to support decision making in the formulation and coating process development.
Purpose
Most oral dosage forms such as tablets and capsules are not suitable for older people with swallowing difficulties. Capsules opening and tablet crushing are commonly used to overcome this problem. In addition to safety and legal concerns, this approach cannot be applied to sustained release products because of the loss of their functionality, consequently causing dose dumping and, undesirable side effects and even toxicity. The number of appropriate medicines for older patients with swallowing difficulties is limited because of the absence of appropriate oral dosage forms. One of the most appropriate forms of medicines for patients with swallowing difficulties are liquid formulations.
To overcome the described issues in older patients with dysphagia, the present study aimed at the development of film-coated sustained release microparticles for use in redispersible multi-dose oral suspensions to ensure facilitated swallowing and acceptable shelf life.
The present study was aimed at the development of a redispersible multi-dose suspension based on coated microparticles to ensure easy swallowing and sustained release of metoprolol succinate. To provide sustained release of metoprolol succinate, the microparticles were prepared by drug loading and Eudragit NM coating in a fluid-bed coater. Compositions of the liquid suspension vehicle were selected to reduce solubility of metoprolol succinate. The effect of vehicle composition and suspension storage time at RT on drug leaching into the suspension vehicle and on the drug release profile were investigated. The approach allowed a redispersible multi-dose suspension of metoprolol microparticles which, after one month storage, displayed negligible drug leaching into the suspension vehicle and a sustained release profile comparable to the profile before storage.
2018.09.07. Development of multi-dose oral sustained release suspensions for ...Valentyn Mohylyuk
The present study was aimed at the development of a re-dispersible multi-dose suspension based on coated microparticles to ensure easy swallowing and sustained release of metoprolol succinate. To provide sustained release of metoprolol succinate, the microparticles were prepared by drug loading and Eudragit® NM coating in a fluid-bed coater. Compositions of the liquid suspension vehicle were selected to reduce solubility of metoprolol succinate. The effect of vehicle composition and suspension storage time at RT on drug leaching into the suspension vehicle and on the drug release profile were investigated. The approach allowed a re-dispersible multi-dose suspension of metoprolol microparticles which, after one month’s storage, displayed negligible drug leaching into the suspension vehicle and a sustained release profile comparable to the profile before storage.
2017.10.18. Обзор мероприятия: Индустрия 4.0: Тенденции в области фармацевтич...Valentyn Mohylyuk
Обзор мероприятия: Международная конференция «Индустрия 4.0: Тенденции в области фармацевтического производства, технологий и упаковки» 18 октября 2017
Course:
"Medicines for older adults: Getting prepared for the scientific and regulatory evolution"
Place: 07 to 08 November 2017, Hotel Das Weitzer, Graz,
Austria
Chairs: Sven Stegemann, Graz University of Technology, Graz, Austria; Capsugel Carsten Timpe, F. Hoffmann-La Roche Ltd., Basle, Switzerland
2016.02.17. Extract from PhD Dissertation (Mohylyuk Valentyn)Valentyn Mohylyuk
ANNOTATION
Mohylyuk V.V. Scientific and practical substantiation of formulation and technology of sustained release matrix tablets. Case study: Trimetazidine dihydrochloride. – Manuscript.
A thesis for the Candidate of Pharmacy Degree in specialty 15.00.01. – Technology of drugs, organization of pharmaceutical business and forensic pharmacy. – Shupyk National Medical Academy of Postgraduate Education, Kyiv, 2016.
Dissertation is dedicated to the study of factors affecting the release kinetics of freely soluble active pharmaceutical ingredient trimetazidine dihydrochloride (TMZ•2HCl) in vitro from matrix tablets produced using direct compression method.
Effect of soluble matrix formers on TMZ•2HCl release profile from matrix tablets was conducted. It was experimentally established that matrix former release prolongation possibility increased with increasing of possibility to form viscous solutions in water: Klucel HXF > Methocel K15M > Polyox WSR-301 > Kollidon K-90 for different polymers and Methocel K100M > K15M > K100LV for same polymers with different molecular weight. Slowdown of release in the release medium with pH 6.8 was due to the interaction of TMZ•2HCl and Carbopol 71G with rubber-like layer formation.
It was experimentally established that effect of insoluble matrix formers on TMZ•2HCl release profile from matrix tablets was in sequence: Ethocel 10 > Precirol ATO 5 ≈ Kollidon SR > Eudragit RSPO. Swelling of Kollidon SR matrix was due to elastic recovery of spherical shape of polymer particles and polyvinyl acetate swelling upon hydration.
Diluents type effect on TMZ•2HCl dissolution profile was investigated. Soluble (sorbitol), insoluble (calcium hydrogen phosphate dihydrate), insoluble and swellable (cellulose microcrystalline) diluents were used. Faster TMZ•2HCl release from Ethocel 10, Kollidon SR and Methocel K4M matrix tablets with sorbitol than Emcompress and Avicel PH-101 was established. During determination of Emcompress and Avicel PH-101 effect on release kinetics from matrix tablets with different matrix formers were established that release was faster using: Avicel PH-101 in insoluble unswellable matrix of Ethocel 10; Emcompress in insoluble swellable matrix of Kollidon SR; Avicel PH-101 in soluble swellable matrix of Methocel K4М. It was established that TMZ•2HCl release kinetics from matrix tablets with Ethocel 10, Kollidon SR and Methocel K4M and Emcompress diluent was higher in pH 1 medium than in pH 6.8 which is consistent with pH-dependent Emcompress solubility.
Soluble diluents particle size effect on TMZ•2HCl dissolution profile was also investigated. Decreasing of TMZ•2HCl dissolution kinetics from Ethocel 10 matrix tablets with lactose and sorbitol particle size increasing was established. The dissolution kinetics from Kollidon
«Тенденции в области фармацевтического производства и технологий в контексте развития украинского фармрынка»
Панельная дискуссия
Конференция началась с панельной дискуссии с участием двух экспертов, работающих в украинских фармацевтических компаниях, – андрея гоя, руководителя департамента исследований и разработок ПАО
«Фармак», и валентина могилюка, менеджера по
стратегическому развитию ООО «Юнифарма».
2016. Dosage Form Optimization: Technology to Advance the Patient-Centric Dru...Valentyn Mohylyuk
A supplement to American Pharmaceutical Review
September / October 2016
Dosage Form Optimization: Technology to Advance the Patient-Centric Drug-Development Process
Catalent Development
2014.09.30. Bioavailability Enhancement Webinar Series: Optimizing Technology Choice to Enhance Bioavailability
Capsugel (Bend Research)
Abstract:
An increasing number of active compounds in pipelines today have properties that require functional formulation to enable exposure and efficacy. Despite many new technology choices, it is often difficult to match the right drug-delivery technology to a given molecule and problem statement. This problem is exacerbated by the need to save time and valuable drug in early development. This webinar describes an efficient strategy for mating enabling drug-delivery technologies with problem statements based on challenging compound properties and product concepts, building on an understanding of gut physiology, key molecule physicochemical properties, and the target product profile.
Company Summary:
Capsugel Dosage Form Solutions designs, develops and manufactures innovative dosage forms addressing bioavailability and other pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation.
Speakers Bio:
Dr. David Vodak
Vice President Bend Research Moderator
Dr. Vodak's areas of expertise are research and development of novel pharmaceutical drug-delivery systems. Dr. Vodak holds a PhD in materials chemistry from the University of Michigan and a B.A. in chemistry from Willamette University.
Dr. David Lyon
Senior Vice President Bend Research
Dr. Lyon is the Senior Vice President at Bend Research. He leads development activities for new technologies, oversees the development of predictive biomodels, and provides technical leadership to the research groups for new and applied technologies.
2016.08.15. rotor powder coating using ethocel ph (dow colorcon)Valentyn Mohylyuk
Spray coatings of ethylcellulose for sustained drug release on multi-particulate dosage forms is common in the pharmaceutical industry, but can be disadvantageous because of long process times, need for organic solvent capabilities, and particulate agglomeration.
Using a rotor process technology, ethylcellulose can be applied to drug layered beads as a dry powder; enabling the user to achieve high levels of weight gain in a short period of time while still demonstrating sustained release.
Information will be presented comparing performance and productivity to traditional solvent-based Wurster coating and aqueous-based Wurster coating.
Функциональные пленочные покрытия и практические аспекты их применения (2016....Valentyn Mohylyuk
Свойства полимеров, а также полимеров в комбинации с пластификатором и пигментом, пропорции этих ингредиентов, метод нанесения пленочных покрытий и технологические параметры нанесения определяют физико-хи-мические свойства конечной оболочки. На мировом фармацевтическом рынке большинство декоративных покрытий твердых лекарственных форм содержат в своем составе полимер гидроксипропилметилцеллюлозу (ГПМЦ), номенклатура используемых полимеров в функциональных оболочках более разнообразна. На рынке вспомогательных веществ, предназначенных для нанесения функциональных пленочных покрытий, предлагаются как отдель-ные компоненты (полимеры, пластификаторы, пигменты), готовые смеси
полимера, пластификатора и пигмента для приготовления суспензии, так
и готовые дисперсии (табл. 1). Функциональные покрытия используют
для решения фармакологических, технологических и маркетинговых задач.
ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ МАТРИЧНИХ ТАБЛЕТОК З ПРОЛОНГОВАНИМ ВИВІЛЬНЕННЯМ ТРИ...Valentyn Mohylyuk
1. Тверда фармацевтична композиція з пролонгованим вивільненням активного фармацевтичного інгредієнта триметазидину або його фармацевтично прийнятної солі, що містить щонайменше один матриксоутворювач та щонайменше одну допоміжну речовину, яка відрізняється тим, що як матриксоутворювач виступає щонайменше один полімер етилцелюлози або фізична суміш полівінілацетату та полівінілпіролідону.
2. Фармацевтична композиція за п. 1, яка відрізняється тим, що полімер або полімери етилцелюлози являють собою целюлозу зі ступенем заміщення на радикал -СН2СН3 47,0-50,0 %.
3. Фармацевтична композиція за п. 1, яка відрізняється тим, що фізична суміш полівінілацетату та полівінілпіролідону має співвідношення 8:2, при цьому полівінілацетат має
молекулярну масу близько 450 000 а. о. м., а полівінілпіролідон має молекулярну масу близько 50 000 а. о. м.
4. Фармацевтична композиція за п. 1, яка відрізняється тим, що містить від 30 до 70 відсотків
за вагою матриксоутворювача, відносно загальної ваги композиції.
5. Фармацевтична композиція за будь-яким з пп. 1-4, яка відрізняється тим, що представлена у
формі таблеток.
6. Фармацевтична композиція за п. 5, яка відрізняється тим, що кожна таблетка містить від 31,5 мг до 38,5 мг триметазидину дигідрохлориду, переважно від 34 мг до 36 мг
Примечание автора: Рис. 4 А и Рис 4 В перепутаны местами
Термин «пеллета» используется в различных отраслях промышленности и несет различную смысловую нагрузку. В фармацевтической промышленности пеллетами называют сыпучие сферообразные частицы, произведенные посредством агломерации тонких порошков или гранул с использованием соответствующего процессного оборудования. Этот термин был введен в 70-х годах прошлого столетия в фармацевтической промышленности в контексте мультипартикулярных систем доставки, которые имеют ряд преимуществ перед монопартикулярными. Данная тема раскрывалась на страницах нашего журнала ранее.
Влияние молекулярной массы поливинилпирролидона на высвобождение триметазид...Valentyn Mohylyuk
Проведено сравнительное исследование влияния молекулярной массы поливинил-пирролидона (ПВП) (Kollidon K17, K25 и K90) на кинетику высвобождения низкомолеку-лярной легкорастворимой (340 мг/мл) модельной субстанции триметазидинадигидро-хлорида из матричной таблетки.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Purpose
Most oral dosage forms such as tablets and capsules are not suitable for older people with swallowing difficulties. Capsules opening and tablet crushing are commonly used to overcome this problem. In addition to safety and legal concerns, this approach cannot be applied to sustained release products because of the loss of their functionality, consequently causing dose dumping and, undesirable side effects and even toxicity. The number of appropriate medicines for older patients with swallowing difficulties is limited because of the absence of appropriate oral dosage forms. One of the most appropriate forms of medicines for patients with swallowing difficulties are liquid formulations.
To overcome the described issues in older patients with dysphagia, the present study aimed at the development of film-coated sustained release microparticles for use in redispersible multi-dose oral suspensions to ensure facilitated swallowing and acceptable shelf life.
The present study was aimed at the development of a redispersible multi-dose suspension based on coated microparticles to ensure easy swallowing and sustained release of metoprolol succinate. To provide sustained release of metoprolol succinate, the microparticles were prepared by drug loading and Eudragit NM coating in a fluid-bed coater. Compositions of the liquid suspension vehicle were selected to reduce solubility of metoprolol succinate. The effect of vehicle composition and suspension storage time at RT on drug leaching into the suspension vehicle and on the drug release profile were investigated. The approach allowed a redispersible multi-dose suspension of metoprolol microparticles which, after one month storage, displayed negligible drug leaching into the suspension vehicle and a sustained release profile comparable to the profile before storage.
2018.09.07. Development of multi-dose oral sustained release suspensions for ...Valentyn Mohylyuk
The present study was aimed at the development of a re-dispersible multi-dose suspension based on coated microparticles to ensure easy swallowing and sustained release of metoprolol succinate. To provide sustained release of metoprolol succinate, the microparticles were prepared by drug loading and Eudragit® NM coating in a fluid-bed coater. Compositions of the liquid suspension vehicle were selected to reduce solubility of metoprolol succinate. The effect of vehicle composition and suspension storage time at RT on drug leaching into the suspension vehicle and on the drug release profile were investigated. The approach allowed a re-dispersible multi-dose suspension of metoprolol microparticles which, after one month’s storage, displayed negligible drug leaching into the suspension vehicle and a sustained release profile comparable to the profile before storage.
2017.10.18. Обзор мероприятия: Индустрия 4.0: Тенденции в области фармацевтич...Valentyn Mohylyuk
Обзор мероприятия: Международная конференция «Индустрия 4.0: Тенденции в области фармацевтического производства, технологий и упаковки» 18 октября 2017
Course:
"Medicines for older adults: Getting prepared for the scientific and regulatory evolution"
Place: 07 to 08 November 2017, Hotel Das Weitzer, Graz,
Austria
Chairs: Sven Stegemann, Graz University of Technology, Graz, Austria; Capsugel Carsten Timpe, F. Hoffmann-La Roche Ltd., Basle, Switzerland
2016.02.17. Extract from PhD Dissertation (Mohylyuk Valentyn)Valentyn Mohylyuk
ANNOTATION
Mohylyuk V.V. Scientific and practical substantiation of formulation and technology of sustained release matrix tablets. Case study: Trimetazidine dihydrochloride. – Manuscript.
A thesis for the Candidate of Pharmacy Degree in specialty 15.00.01. – Technology of drugs, organization of pharmaceutical business and forensic pharmacy. – Shupyk National Medical Academy of Postgraduate Education, Kyiv, 2016.
Dissertation is dedicated to the study of factors affecting the release kinetics of freely soluble active pharmaceutical ingredient trimetazidine dihydrochloride (TMZ•2HCl) in vitro from matrix tablets produced using direct compression method.
Effect of soluble matrix formers on TMZ•2HCl release profile from matrix tablets was conducted. It was experimentally established that matrix former release prolongation possibility increased with increasing of possibility to form viscous solutions in water: Klucel HXF > Methocel K15M > Polyox WSR-301 > Kollidon K-90 for different polymers and Methocel K100M > K15M > K100LV for same polymers with different molecular weight. Slowdown of release in the release medium with pH 6.8 was due to the interaction of TMZ•2HCl and Carbopol 71G with rubber-like layer formation.
It was experimentally established that effect of insoluble matrix formers on TMZ•2HCl release profile from matrix tablets was in sequence: Ethocel 10 > Precirol ATO 5 ≈ Kollidon SR > Eudragit RSPO. Swelling of Kollidon SR matrix was due to elastic recovery of spherical shape of polymer particles and polyvinyl acetate swelling upon hydration.
Diluents type effect on TMZ•2HCl dissolution profile was investigated. Soluble (sorbitol), insoluble (calcium hydrogen phosphate dihydrate), insoluble and swellable (cellulose microcrystalline) diluents were used. Faster TMZ•2HCl release from Ethocel 10, Kollidon SR and Methocel K4M matrix tablets with sorbitol than Emcompress and Avicel PH-101 was established. During determination of Emcompress and Avicel PH-101 effect on release kinetics from matrix tablets with different matrix formers were established that release was faster using: Avicel PH-101 in insoluble unswellable matrix of Ethocel 10; Emcompress in insoluble swellable matrix of Kollidon SR; Avicel PH-101 in soluble swellable matrix of Methocel K4М. It was established that TMZ•2HCl release kinetics from matrix tablets with Ethocel 10, Kollidon SR and Methocel K4M and Emcompress diluent was higher in pH 1 medium than in pH 6.8 which is consistent with pH-dependent Emcompress solubility.
Soluble diluents particle size effect on TMZ•2HCl dissolution profile was also investigated. Decreasing of TMZ•2HCl dissolution kinetics from Ethocel 10 matrix tablets with lactose and sorbitol particle size increasing was established. The dissolution kinetics from Kollidon
«Тенденции в области фармацевтического производства и технологий в контексте развития украинского фармрынка»
Панельная дискуссия
Конференция началась с панельной дискуссии с участием двух экспертов, работающих в украинских фармацевтических компаниях, – андрея гоя, руководителя департамента исследований и разработок ПАО
«Фармак», и валентина могилюка, менеджера по
стратегическому развитию ООО «Юнифарма».
2016. Dosage Form Optimization: Technology to Advance the Patient-Centric Dru...Valentyn Mohylyuk
A supplement to American Pharmaceutical Review
September / October 2016
Dosage Form Optimization: Technology to Advance the Patient-Centric Drug-Development Process
Catalent Development
2014.09.30. Bioavailability Enhancement Webinar Series: Optimizing Technology Choice to Enhance Bioavailability
Capsugel (Bend Research)
Abstract:
An increasing number of active compounds in pipelines today have properties that require functional formulation to enable exposure and efficacy. Despite many new technology choices, it is often difficult to match the right drug-delivery technology to a given molecule and problem statement. This problem is exacerbated by the need to save time and valuable drug in early development. This webinar describes an efficient strategy for mating enabling drug-delivery technologies with problem statements based on challenging compound properties and product concepts, building on an understanding of gut physiology, key molecule physicochemical properties, and the target product profile.
Company Summary:
Capsugel Dosage Form Solutions designs, develops and manufactures innovative dosage forms addressing bioavailability and other pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation.
Speakers Bio:
Dr. David Vodak
Vice President Bend Research Moderator
Dr. Vodak's areas of expertise are research and development of novel pharmaceutical drug-delivery systems. Dr. Vodak holds a PhD in materials chemistry from the University of Michigan and a B.A. in chemistry from Willamette University.
Dr. David Lyon
Senior Vice President Bend Research
Dr. Lyon is the Senior Vice President at Bend Research. He leads development activities for new technologies, oversees the development of predictive biomodels, and provides technical leadership to the research groups for new and applied technologies.
2016.08.15. rotor powder coating using ethocel ph (dow colorcon)Valentyn Mohylyuk
Spray coatings of ethylcellulose for sustained drug release on multi-particulate dosage forms is common in the pharmaceutical industry, but can be disadvantageous because of long process times, need for organic solvent capabilities, and particulate agglomeration.
Using a rotor process technology, ethylcellulose can be applied to drug layered beads as a dry powder; enabling the user to achieve high levels of weight gain in a short period of time while still demonstrating sustained release.
Information will be presented comparing performance and productivity to traditional solvent-based Wurster coating and aqueous-based Wurster coating.
Функциональные пленочные покрытия и практические аспекты их применения (2016....Valentyn Mohylyuk
Свойства полимеров, а также полимеров в комбинации с пластификатором и пигментом, пропорции этих ингредиентов, метод нанесения пленочных покрытий и технологические параметры нанесения определяют физико-хи-мические свойства конечной оболочки. На мировом фармацевтическом рынке большинство декоративных покрытий твердых лекарственных форм содержат в своем составе полимер гидроксипропилметилцеллюлозу (ГПМЦ), номенклатура используемых полимеров в функциональных оболочках более разнообразна. На рынке вспомогательных веществ, предназначенных для нанесения функциональных пленочных покрытий, предлагаются как отдель-ные компоненты (полимеры, пластификаторы, пигменты), готовые смеси
полимера, пластификатора и пигмента для приготовления суспензии, так
и готовые дисперсии (табл. 1). Функциональные покрытия используют
для решения фармакологических, технологических и маркетинговых задач.
ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ МАТРИЧНИХ ТАБЛЕТОК З ПРОЛОНГОВАНИМ ВИВІЛЬНЕННЯМ ТРИ...Valentyn Mohylyuk
1. Тверда фармацевтична композиція з пролонгованим вивільненням активного фармацевтичного інгредієнта триметазидину або його фармацевтично прийнятної солі, що містить щонайменше один матриксоутворювач та щонайменше одну допоміжну речовину, яка відрізняється тим, що як матриксоутворювач виступає щонайменше один полімер етилцелюлози або фізична суміш полівінілацетату та полівінілпіролідону.
2. Фармацевтична композиція за п. 1, яка відрізняється тим, що полімер або полімери етилцелюлози являють собою целюлозу зі ступенем заміщення на радикал -СН2СН3 47,0-50,0 %.
3. Фармацевтична композиція за п. 1, яка відрізняється тим, що фізична суміш полівінілацетату та полівінілпіролідону має співвідношення 8:2, при цьому полівінілацетат має
молекулярну масу близько 450 000 а. о. м., а полівінілпіролідон має молекулярну масу близько 50 000 а. о. м.
4. Фармацевтична композиція за п. 1, яка відрізняється тим, що містить від 30 до 70 відсотків
за вагою матриксоутворювача, відносно загальної ваги композиції.
5. Фармацевтична композиція за будь-яким з пп. 1-4, яка відрізняється тим, що представлена у
формі таблеток.
6. Фармацевтична композиція за п. 5, яка відрізняється тим, що кожна таблетка містить від 31,5 мг до 38,5 мг триметазидину дигідрохлориду, переважно від 34 мг до 36 мг
Примечание автора: Рис. 4 А и Рис 4 В перепутаны местами
Термин «пеллета» используется в различных отраслях промышленности и несет различную смысловую нагрузку. В фармацевтической промышленности пеллетами называют сыпучие сферообразные частицы, произведенные посредством агломерации тонких порошков или гранул с использованием соответствующего процессного оборудования. Этот термин был введен в 70-х годах прошлого столетия в фармацевтической промышленности в контексте мультипартикулярных систем доставки, которые имеют ряд преимуществ перед монопартикулярными. Данная тема раскрывалась на страницах нашего журнала ранее.
Влияние молекулярной массы поливинилпирролидона на высвобождение триметазид...Valentyn Mohylyuk
Проведено сравнительное исследование влияния молекулярной массы поливинил-пирролидона (ПВП) (Kollidon K17, K25 и K90) на кинетику высвобождения низкомолеку-лярной легкорастворимой (340 мг/мл) модельной субстанции триметазидинадигидро-хлорида из матричной таблетки.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.